J&J's TMC435 Joins The Pharmasset Club
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmasset and J&J's Tibotec unit will initiate a Phase II study evaluating the combination of the investigational nucleotide polymerase inhibitor PSI-7977 and protease inhibitor TMC435.
You may also be interested in...
Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset
The planned purchase price of $11 billion, or $137 a share, an 89% premium over Pharmasset’s closing price on Nov. 18, is by far the highest ever paid for a clinical-stage biotech.
Sweden's Medivir Strengthens Executive Team, Aims To Become Profitable Specialty Firm
With its hepatitis C protease inhibitor progressing in Phase III, Medivir starts to transform itself into a profitable specialty pharmaceutical company.
Sweden's Medivir Strengthens Executive Team, Aims To Become Profitable Specialty Firm
With its hepatitis C protease inhibitor progressing in Phase III, Medivir starts to transform itself into a profitable specialty pharmaceutical company.